Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : TCGX
Deal Size : $120.0 million
Deal Type : Series B Financing
Pheon Therapeutics Announces $120M Series B Financing for ADC Pipeline Development
Details : The financing aims to fund the clinical development of company lead product PHN-010, which is being evaluated in the early-stage trial studies for the treatment of neoplasms.
Product Name : PHN-010
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 21, 2024
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : TCGX
Deal Size : $120.0 million
Deal Type : Series B Financing
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Brandon Capital
Deal Size : $68.0 million
Deal Type : Series A Financing
Brandon Capital Co-Leads USD 68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Details : The investment will enable Pheon to advance its lead ADC program PHN-010, to clinical proof-of-concept and establish a pipeline of novel ADCs. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors.
Product Name : PHN-010
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Brandon Capital
Deal Size : $68.0 million
Deal Type : Series A Financing
Reset All
